145 related articles for article (PubMed ID: 23450802)
1. Fluorescence lifetime imaging of biosensor peptide phosphorylation in single live cells.
Damayanti NP; Parker LL; Irudayaraj JM
Angew Chem Int Ed Engl; 2013 Apr; 52(14):3931-4. PubMed ID: 23450802
[No Abstract] [Full Text] [Related]
2. ONIOM DFT/PM3 calculation on the interaction between STI-571 and abelson tyrosine kinase.
Xiong YZ; Chen PY
J Mol Model; 2008 Nov; 14(11):1083-6. PubMed ID: 18663490
[TBL] [Abstract][Full Text] [Related]
3. Conformation-selective inhibitors reveal differences in the activation and phosphate-binding loops of the tyrosine kinases Abl and Src.
Hari SB; Perera BG; Ranjitkar P; Seeliger MA; Maly DJ
ACS Chem Biol; 2013 Dec; 8(12):2734-43. PubMed ID: 24106839
[TBL] [Abstract][Full Text] [Related]
4. Steered molecular dynamics simulations reveal the likelier dissociation pathway of imatinib from its targeting kinases c-Kit and Abl.
Yang LJ; Zou J; Xie HZ; Li LL; Wei YQ; Yang SY
PLoS One; 2009 Dec; 4(12):e8470. PubMed ID: 20041122
[TBL] [Abstract][Full Text] [Related]
5. NMR reveals the allosteric opening and closing of Abelson tyrosine kinase by ATP-site and myristoyl pocket inhibitors.
Skora L; Mestan J; Fabbro D; Jahnke W; Grzesiek S
Proc Natl Acad Sci U S A; 2013 Nov; 110(47):E4437-45. PubMed ID: 24191057
[TBL] [Abstract][Full Text] [Related]
6. Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance.
Azam M; Nardi V; Shakespeare WC; Metcalf CA; Bohacek RS; Wang Y; Sundaramoorthi R; Sliz P; Veach DR; Bornmann WG; Clarkson B; Dalgarno DC; Sawyer TK; Daley GQ
Proc Natl Acad Sci U S A; 2006 Jun; 103(24):9244-9. PubMed ID: 16754879
[TBL] [Abstract][Full Text] [Related]
7. BIRB-796 is not an effective ABL(T315I) inhibitor.
O'Hare T; Druker BJ
Nat Biotechnol; 2005 Oct; 23(10):1209-10; author reply 1210-1. PubMed ID: 16211050
[No Abstract] [Full Text] [Related]
8. A molecular mechanics model for imatinib and imatinib:kinase binding.
Aleksandrov A; Simonson T
J Comput Chem; 2010 May; 31(7):1550-60. PubMed ID: 20020482
[TBL] [Abstract][Full Text] [Related]
9. Analysis of imatinib and sorafenib binding to p38alpha compared with c-Abl and b-Raf provides structural insights for understanding the selectivity of inhibitors targeting the DFG-out form of protein kinases.
Namboodiri HV; Bukhtiyarova M; Ramcharan J; Karpusas M; Lee Y; Springman EB
Biochemistry; 2010 May; 49(17):3611-8. PubMed ID: 20337484
[TBL] [Abstract][Full Text] [Related]
10. Tyrosine kinase inhibition: Ligand binding and conformational change in c-Kit and c-Abl.
Healy EF; Johnson S; Hauser CR; King PJ
FEBS Lett; 2009 Sep; 583(17):2899-906. PubMed ID: 19660459
[TBL] [Abstract][Full Text] [Related]
11. A magnetic bead-based protein kinase assay with dual detection techniques.
Zhou G; Sylvester JE; Wu D; Veach DR; Kron SJ
Anal Biochem; 2011 Jan; 408(1):5-11. PubMed ID: 20807497
[TBL] [Abstract][Full Text] [Related]
12. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571).
Nagar B; Bornmann WG; Pellicena P; Schindler T; Veach DR; Miller WT; Clarkson B; Kuriyan J
Cancer Res; 2002 Aug; 62(15):4236-43. PubMed ID: 12154025
[TBL] [Abstract][Full Text] [Related]
13. Explaining why Gleevec is a specific and potent inhibitor of Abl kinase.
Lin YL; Meng Y; Jiang W; Roux B
Proc Natl Acad Sci U S A; 2013 Jan; 110(5):1664-9. PubMed ID: 23319661
[TBL] [Abstract][Full Text] [Related]
14. Inhibitors of the Abl kinase directed at either the ATP- or myristate-binding site.
Fabbro D; Manley PW; Jahnke W; Liebetanz J; Szyttenholm A; Fendrich G; Strauss A; Zhang J; Gray NS; Adrian F; Warmuth M; Pelle X; Grotzfeld R; Berst F; Marzinzik A; Cowan-Jacob SW; Furet P; Mestan J
Biochim Biophys Acta; 2010 Mar; 1804(3):454-62. PubMed ID: 20152788
[TBL] [Abstract][Full Text] [Related]
15. Detection of early Abl kinase activation after ionizing radiation by using a peptide biosensor.
Tang J; Wang JY; Parker LL
Chembiochem; 2012 Mar; 13(5):665-73. PubMed ID: 22334513
[TBL] [Abstract][Full Text] [Related]
16. Backbone NMR resonance assignment of the Abelson kinase domain in complex with imatinib.
Vajpai N; Strauss A; Fendrich G; Cowan-Jacob SW; Manley PW; Jahnke W; Grzesiek S
Biomol NMR Assign; 2008 Jun; 2(1):41-2. PubMed ID: 19636920
[TBL] [Abstract][Full Text] [Related]
17. New effective inhibitors of the Abelson kinase.
Kraus GA; Gupta V; Mokhtarian M; Mehanovic S; Nilsen-Hamilton M
Bioorg Med Chem; 2010 Sep; 18(17):6316-21. PubMed ID: 20674368
[TBL] [Abstract][Full Text] [Related]
18. The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants.
Tokarski JS; Newitt JA; Chang CY; Cheng JD; Wittekind M; Kiefer SE; Kish K; Lee FY; Borzillerri R; Lombardo LJ; Xie D; Zhang Y; Klei HE
Cancer Res; 2006 Jun; 66(11):5790-7. PubMed ID: 16740718
[TBL] [Abstract][Full Text] [Related]
19. Abl tyrosine kinase promotes dorsal ruffles but restrains lamellipodia extension during cell spreading on fibronectin.
Jin H; Wang JY
Mol Biol Cell; 2007 Oct; 18(10):4143-54. PubMed ID: 17686996
[TBL] [Abstract][Full Text] [Related]
20. Gleevec target Abl important for normal immune activation of T cells.
Cancer Biol Ther; 2004 Aug; 3(8):704. PubMed ID: 15751157
[No Abstract] [Full Text] [Related]
[Next] [New Search]
